论文部分内容阅读
3月29日,安进在美国心脏病学会(ACC)年会上发布了3期临床研究GAUSS-2和LAPLACE-2的详细结果,结果显示其试验药物PCSK9抑制剂Evolocumab可明显降低他汀类药物耐受患者的低密度脂蛋白胆固醇(LDL-C)水平。该公司指出,今年将向美国提交Evolocumab的上市申请。这款药物预期与辉瑞处于后期试验的同类候选药物进行竞争。此外,竞争者还有来自赛诺菲及其合作伙伴再生元的一款药物。分析师已预测,如果获得批准,假定保险公司同
On March 29, Amgen released detailed results of phase 3 clinical studies GAUSS-2 and LAPLACE-2 at the annual meeting of the American College of Cardiology (ACC). The results showed that the test drug PCSK9 inhibitor Evolocumab significantly reduced statin Tolerance in patients with low-density lipoprotein cholesterol (LDL-C) levels. The company said it will file a filing with Evolocumab in the United States this year. The drug is expected to compete with similar Pfizer candidate drugs of late-stage trial. In addition, competitors also have a drug from Sanofi and its partner Renewables. Analysts have predicted that if approved, it is assumed that insurance companies are the same